Loading news...
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close.
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the medium term.
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade.
Shares of SoundHound AI have been all over the place of late, but that extreme volatility appears to have run its course. Viking Therapeutics wasn't the first name to the weight loss drug party.
Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.22, moving 5.49% from the previous trading session.
Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may benefit from this market in just a few years.
Viking Therapeutics, Inc. (VKTX) closed at $34.09 in the latest trading session, marking a +2.13% move from the prior day.
Summary Tema Heart and Health ETF raised its stake in Viking Therapeutics Inc (VKTX) by 146.02%, purchasing 5,473 shares to own 9,221 shares valued at ab
Viking Therapeutics doesn't have any approved products in its portfolio, but VK2735 has shown encouraging weight loss results in clinical trials. PayPal's growth has been poor in recent quarters, but the company has been making moves that could give its business a boost in the future.
Viking Therapeutics' price target implies a juicy upside from its current levels. The stock's most important catalysts will likely have to wait until next year.
Inspire Advisors LLC purchased a new position in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,615 shares of the biotechnology company's stock, valued at approximately $594,000. Other institutional investors and hedge funds
Viking Therapeutics' stock was volatile in 2025 due to clinical trial results. VK2735's oral form faced safety concerns but remains promising.
The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk.
Viking Therapeutics, Inc. (VKTX) reached $31.86 at the closing of the latest trading day, reflecting a -7.21% change compared to its last close.
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Weight-loss drug developer Viking Therapeutics CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as drugmakers seek to tap into the potential $150 billion market.
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the publication of the results of the company's Phase 2 VENTURE clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.